ReviewFrontiers in immunology2021
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- A Meta-Analysis on the Immunogenicity of Homologous versus Heterologous Immunization Regimens against SARS-CoV-2 Beta, Delta, and Omicron BA.1 VoCs in Healthy Adults.Journal of microbiology and biotechnology · 2025Pooled it
- Extensive cross-reactive T cell epitopes across SARS-CoV-2 Omicron variant spikes with finite immune evasion mutations.Journal of translational medicine · 2025Article
- Genomic Analysis and Tracking of SARS-CoV-2 Variants in Gwangju, South Korea, From 2020 to 2022.Influenza and other respiratory viruses · 2024Article
- Nanobody engineering for SARS-CoV-2 neutralization and detection.Microbiology spectrum · 2024Article
- A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.Molecular therapy. Methods & clinical development · 2023Article
- Analysis of the COVID-19 pandemic using a compartmental model with time-varying parameters fitted by a genetic algorithm.Expert systems with applications · 2023Article
- An assessment of the strategy and status of COVID-19 vaccination in India.Immunologic research · 2023Review
- Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources.Infectious diseases and therapy · 2023Article
- Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform.iScience · 2023Article
- Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study.Journal of medical virology · 2023Article
- SARS-CoV-2 evolves to reduce but not abolish neutralizing action.Journal of medical virology · 2023Article
- Brewpitopes: a pipeline to refine B-cell epitope predictions during public health emergencies.Frontiers in immunology · 2023Article
- SARS-CoV-2: An Analysis of the Vaccine Candidates Tested in Combatting and Eliminating the COVID-19 Virus.Vaccines · 2022Review
- The Tragedy of Liberal Democratic Governance in the Face of Global Threats.Frontiers in public health · 2022Article
- Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) pandemic is a serious threat to global public health and social and economic development. Various vaccine platforms have been developed rapidly and unprecedentedly, and at least 16 vaccines receive emergency use authorization (EUA). However, the causative pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has continued to evolve and mutate, emerging lots of viral variants. Several variants have successfully become the predominant strains and spread all over the world because of their ability to evade the pre-existing immunity obtained after previous infections with prototype strain or immunizations. Here, we summarized the prevalence and biological structure of these variants and the efficacy of currently used vaccines against the SARS-CoV-2 variants to provide guidance on how to design vaccines more rationally against the variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.